CN112293731A - 一种提升益生菌在肠道内成活率和定植率的方法 - Google Patents
一种提升益生菌在肠道内成活率和定植率的方法 Download PDFInfo
- Publication number
- CN112293731A CN112293731A CN202011194725.0A CN202011194725A CN112293731A CN 112293731 A CN112293731 A CN 112293731A CN 202011194725 A CN202011194725 A CN 202011194725A CN 112293731 A CN112293731 A CN 112293731A
- Authority
- CN
- China
- Prior art keywords
- million cfu
- lactobacillus
- hundred million
- powder
- light fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 49
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 49
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000004083 survival effect Effects 0.000 title claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 43
- 239000012530 fluid Substances 0.000 claims abstract description 42
- 230000001580 bacterial effect Effects 0.000 claims abstract description 29
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 24
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 19
- 210000002784 stomach Anatomy 0.000 claims abstract description 15
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 14
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 10
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 10
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 10
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 10
- 244000247812 Amorphophallus rivieri Species 0.000 claims abstract description 9
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims abstract description 9
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 9
- 229920002752 Konjac Polymers 0.000 claims abstract description 9
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 9
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 9
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 9
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 9
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 9
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 9
- 244000134552 Plantago ovata Species 0.000 claims abstract description 9
- 235000003421 Plantago ovata Nutrition 0.000 claims abstract description 9
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 9
- 239000000252 konjac Substances 0.000 claims abstract description 9
- 235000010485 konjac Nutrition 0.000 claims abstract description 9
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 9
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 9
- 239000011782 vitamin Substances 0.000 claims abstract description 9
- 229940088594 vitamin Drugs 0.000 claims abstract description 9
- 229930003231 vitamin Natural products 0.000 claims abstract description 9
- 235000013343 vitamin Nutrition 0.000 claims abstract description 9
- 244000060011 Cocos nucifera Species 0.000 claims abstract description 8
- 235000013162 Cocos nucifera Nutrition 0.000 claims abstract description 8
- 235000016623 Fragaria vesca Nutrition 0.000 claims abstract description 8
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims abstract description 8
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 8
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 8
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 8
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 8
- 235000020235 chia seed Nutrition 0.000 claims abstract description 8
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims abstract description 8
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 8
- 235000021092 sugar substitutes Nutrition 0.000 claims abstract description 8
- 239000003765 sweetening agent Substances 0.000 claims abstract description 8
- 235000021119 whey protein Nutrition 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 240000009088 Fragaria x ananassa Species 0.000 claims abstract 3
- 241000894006 Bacteria Species 0.000 claims description 31
- 230000000529 probiotic effect Effects 0.000 claims description 23
- 235000013312 flour Nutrition 0.000 claims description 8
- 235000012054 meals Nutrition 0.000 claims description 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 7
- -1 compound vitamin Chemical class 0.000 claims description 7
- 229920001202 Inulin Polymers 0.000 claims description 5
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 5
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 5
- 229940029339 inulin Drugs 0.000 claims description 5
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 5
- 239000000832 lactitol Substances 0.000 claims description 5
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 5
- 229960003451 lactitol Drugs 0.000 claims description 5
- 235000010448 lactitol Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000009223 Psyllium Substances 0.000 claims description 4
- 239000010903 husk Substances 0.000 claims description 4
- 229940070687 psyllium Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 210000004211 gastric acid Anatomy 0.000 abstract description 6
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 6
- 239000003833 bile salt Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 15
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000220223 Fragaria Species 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 206010065764 Mucosal infection Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 241000152447 Hades Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241001134453 Lista Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000009815 adipogenic differentiation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000010034 metabolic health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/03—Products from fruits or vegetables; Preparation or treatment thereof consisting of whole pieces or fragments without mashing the original pieces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/115—Konjak; Konntaku
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提出了一种益生菌,包括菌条和轻流质,所述菌条含有益生元、草莓水果粉、植物乳杆菌LP45、乳双歧杆菌BAL531、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、鼠李糖乳杆菌LR519、两歧双歧杆菌TMC3115、罗伊氏乳杆菌L840、格氏乳杆菌L838和动物双歧杆菌乳双歧亚种B420;所述轻流质,包括脱脂乳粉、麦芽糊精、浓缩乳清蛋白粉、果粉、魔芋粉、椰粉、代糖、冻干果粒、奇亚籽种子、圆苞车前子壳、复配维生素。本发明还提出了一种提升益生菌在肠道内成活率和定植率的方法,采用先空腹服用轻流质,再将菌条与轻流质混合后服用的方式,先服用的轻流质中和胃酸和胆盐,然后菌条与轻流质充分融合后,益生菌菌群成功定植在肠粘膜处。
Description
技术领域
本发明涉及益生菌的技术领域,特别涉及一种提升益生菌在肠道内成活率和定植率的方法。
背景技术
现有的口服益生菌制剂,大致分为两种:一种是饭后服用,一种是空腹服用。其中饭后服用的优点是食物可以中和胃酸,降低对益生菌的腐蚀;缺点是肠胃里食物的积存,会让益生菌形成缓慢移动和滞留,这个过程会让益生菌的活性加速衰减。而空腹服用的优点是肠胃中没有食物积存,通过性好;不足在于此时的胃酸和胆盐较多,没有其他阻拦,会大量腐蚀益生菌。
因此亟需研究一种既能够降低胃酸胆盐对益生菌的腐蚀,让益生菌高效的通过消化管腔,有能够提高抵达肠道益生菌成活率和定植率的方法。
发明内容
本发明提出一种提升益生菌在肠道内成活率和定植率的方法,解决了现有技术中益生菌高效通过消化管腔和提高肠道益生菌成活率、定植率不能兼顾的问题。
本发明的技术方案是这样实现的:
一种益生菌,其特征在于,
所述菌条,包括以下重量份的组分:
益生元1.1~2.58g、草莓水果粉0.1~0.4g、植物乳杆菌LP45 500~800亿CFU、乳双歧杆菌BAL531 5~20亿CFU、嗜酸乳杆菌La28 5~20亿CFU、副干酪乳杆菌YMC1069 4~25亿CFU、鼠李糖乳杆菌LR519 4~20亿CFU、两歧双歧杆菌TMC3115 8~20亿CFU、罗伊氏乳杆菌L840 4~15亿CFU、格氏乳杆菌L838 4~15亿CFU和动物双歧杆菌乳双歧亚种B420 5~30亿CFU;
所述轻流质,包括以下重量份的组分:
脱脂乳粉3~10g、麦芽糊精1~10g、浓缩乳清蛋白粉1~3g、果粉0.5~4g、魔芋粉0.1~2g、椰粉1~7g、代糖2~9g、冻干果粒0.5~3g、奇亚籽种子0.4~2.5g、圆苞车前子壳1~5g、复配维生素0.1~0.3g。
可选地,所述菌条,包括以下重量份的组分:
益生元1.8g、草莓水果粉0.3g、植物乳杆菌LP45 650亿CFU、乳双歧杆菌BAL531 14亿CFU、嗜酸乳杆菌La28 15亿CFU、副干酪乳杆菌YMC1069 15亿CFU、鼠李糖乳杆菌LR519 12亿CFU、两歧双歧杆菌TMC3115 14亿CFU、罗伊氏乳杆菌L840 10亿CFU、格氏乳杆菌L838 10亿CFU和动物双歧杆菌乳双歧亚种B420 18亿CFU;
所述轻流质,包括以下重量份的组分:
脱脂乳粉7g、麦芽糊精5g、浓缩乳清蛋白粉2g、果粉2g、魔芋粉0.5g、椰粉3g、代糖5g、冻干果粒2g、奇亚籽种子1.5g、圆苞车前子壳2g、复配维生素0.2g。
可选地,所述益生元为低聚异麦芽糖0.5~0.9g、质量分数小于等于25%的菊粉0.2~0.68g、乳糖醇0.2~0.4g、低聚果糖0.1~0.4g、质量分数小于等于5%的低聚木糖0.1~0.2g混合而成。
可选地,所述益生菌为粉剂。
本发明还提供了一种提升益生菌在肠道内成活率和定植率的方法,基于上述益生菌,饭前0.5~1小时空腹服用80~100ml轻流质,然后将菌条与100~120ml轻流质水融混匀后,再服用下去。
本发明的有益效果是:
本发明突破了传统方式的益生菌制剂配方,并先采用空腹服用轻流质,菌条与轻流质混合后再服用的方式,先服用的轻流质降低腐蚀性,中和胃酸和胆盐,在胃肠道以及胃壁上,进而在短时间内形成一个相对通畅的管腔环境;然后菌条与轻流质充分融合后,为菌条加上了一道厚厚的胶原质保护层,顺利抵达肠道后,人体肠道中能够提供菌群黏附和定植的空间有限,当先服用轻流质中的粗纤维清理肠粘膜上的有害菌后,让到达一定的量值的益生菌粘附在清理出来的位置上时,有害菌失去存活的住所,顺着肠道排出体外,益生菌菌群成功定植在肠粘膜处,可直接作用到肠上皮细胞中,通过调节肠屏障功能、固有免疫和适应性防御来调节上皮细胞对有害菌的防御能力;再加上轻流质和菌条中富含的益生元,为有益菌提供了充足的食物,让有益菌在肠粘膜上长期的定植与繁衍,增强肠道粘膜和系统的免疫反应,维护健康肠道,可以持续阻止病原菌的黏附和定植,为肠壁提供能量,竞争营养和定植位点,抵制有害菌,可能减轻免疫系统超敏性,防止粘膜感染,降低了大肠杆菌与粘膜的粘附性。
具体实施方式
为使本领域具有普通知识的人员可了解本发明的特点及效果,以下谨就说明书及申请专利范围中提及的术语及用语进行一般性的说明及定义。除非另有指明,否则文中使用的所有技术及科学上的字词,皆具有本领域技术人员对于本发明所了解的通常意义,当有冲突情形时,应以本说明书的定义为准。
在本文中,用语“包含”、“包括”、“具有”、“含有”或其他任何类似用语均属于开放性连接词(open-ended transitional phrase),其意欲涵盖非排他性的包括物。举例而言,含有复数要素的一组合物或制品并不仅限于本文所列出的这些要素而已,而是还可包括未明确列出但却是该组合物或制品通常固有的其他要素。除此之外,除非有相反的明确说明,否则用语“或”是指涵盖性的“或”,而不是指排他性的“或”。例如,以下任何一种情况均满足条件“A或B”:A为真(或存在)且B为伪(或不存在)、A为伪(或不存在)且B为真(或存在)、A和B均为真(或存在)。此外,在本文中,用语“包含”、“包括”、“具有”、“含有”的解读应视为已具体公开并同时涵盖“由…所组成”及“实质上由…所组成”等封闭式或半封闭式连接词。
在本文中,所有以数值范围或百分比范围形式界定的特征或条件仅是为了简洁及方便。据此,数值范围或百分比范围的描述应视为已涵盖且具体公开所有可能的次级范围及范围内的个别数值,特别是整数数值。举例而言,“1至8”的范围描述应视为已经具体公开如1至7、2至8、2至6、3至6、4至8、3至8等等所有次级范围,特别是由所有整数数值所界定的次级范围,且应视为已经具体公开范围内如1、2、3、4、5、6、7、8等个别数值。除非另有指明,否则前述解释方法适用于本发明全文的所有内容,不论范围广泛与否。
若数量或其他数值或参数是以范围、较佳范围或一系列上限与下限表示,则其应理解成是本文已特定公开了由任一对该范围的上限或较佳值与该范围的下限或较佳值构成的所有范围,不论这些范围是否有分别公开。此外,本文中若提到数值的范围时,除非另有说明,否则该范围应包括其端点以及范围内的所有整数与分数。
在本文中,在可实现发明目的的前提下,数值应理解成具有该数值有效位数的精确度。举例来说,数字40.0则应理解成涵盖从39.50至40.49的范围。在本文中,对于使用马库什群组(Markush group)或选项式用语以描述本发明特征或实例的情形,本领域技术人员应了解马库什群组或选项列表内所有要素的次级群组或任何个别要素亦可用于描述本发明。举例而言,若X描述成“选自于由X1、X2及X3所组成的群组”,亦表示已经完全描述出X为X1的主张与X为X1及/或X2的主张。再者,对于使用马库什群组或选项式用语以描述本发明的特征或实例的情况,本领域技术人员应了解马库什群组或选项列表内所有要素的次级群组或个别要素的任何组合亦可用于描述本发明。据此,举例而言,若X描述成“选自于由X1、X2及X3所组成的群组”,且Y描述成“选自于由Y1、Y2及Y3所组成的群组”,则表示已经完全描述出X为X1或X2或X3而Y为Y1或Y2或Y3的主张。
以下具体实施方式本质上仅是例示性,且并不欲限制本发明及其用途。此外,本文并不受前述现有技术或发明内容或以下具体实施方式或实施例中所描述的任何理论的限制。
本发明所用植物乳杆菌LP45、乳双歧杆菌BAL531、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、鼠李糖乳杆菌LR519、两歧双歧杆菌TMC3115、罗伊氏乳杆菌L840、格氏乳杆菌L838购自河北一然生物科技有限公司,和动物双歧杆菌乳双歧亚种购自丹尼斯克(中国)有限公司。
实施例1:
一种益生菌,其特征在于,
包括菌条和轻流质,
所述菌条,包括以下重量份的组分:
益生元1.1g、草莓水果粉0.1g、植物乳杆菌LP45 500亿CFU、乳双歧杆菌BAL531 5亿CFU、嗜酸乳杆菌La28 5亿CFU、副干酪乳杆菌YMC1069 4亿CFU、鼠李糖乳杆菌LR519 4亿CFU、两歧双歧杆菌TMC3115 8亿CFU、罗伊氏乳杆菌L840 4亿CFU、格氏乳杆菌L838 4亿CFU和动物双歧杆菌乳双歧亚种B420 5亿CFU;其中益生元为低聚异麦芽糖0.5g、质量分数小于等于25%的菊粉0.2g、乳糖醇0.2g、低聚果糖0.1g、质量分数小于等于5%的低聚木糖0.1g混合而成;
所述轻流质,包括以下重量份的组分:
脱脂乳粉3g、麦芽糊精1g、浓缩乳清蛋白粉1g、果粉0.5g、魔芋粉0.1g、椰粉1g、代糖2g、冻干果粒0.5g、奇亚籽种子0.4g、圆苞车前子壳1g、复配维生素0.1g。
本实施例本发明还提供了一种提升益生菌在肠道内成活率和定植率的方法,基于上述益生菌,饭前0.5~1小时空腹服用80~100ml轻流质,然后将菌条与100~120ml轻流质水融混匀后,再服用下去。
实施例2:
一种益生菌,其特征在于,
包括菌条和轻流质,
所述菌条,包括以下重量份的组分:
益生元1.8g、草莓水果粉0.3g、植物乳杆菌LP45 650亿CFU、乳双歧杆菌BAL531 14亿CFU、嗜酸乳杆菌La28 15亿CFU、副干酪乳杆菌YMC1069 15亿CFU、鼠李糖乳杆菌LR519 12亿CFU、两歧双歧杆菌TMC3115 14亿CFU、罗伊氏乳杆菌L840 10亿CFU、格氏乳杆菌L838 10亿CFU和动物双歧杆菌乳双歧亚种B420 18亿CFU;其中益生元为低聚异麦芽糖0.7g、质量分数小于等于25%的菊粉0.5g、乳糖醇0.3g、低聚果糖0.2g、质量分数小于等于5%的低聚木糖0.1g混合而成;
所述轻流质,包括以下重量份的组分:
脱脂乳粉7g、麦芽糊精5g、浓缩乳清蛋白粉2g、果粉2g、魔芋粉0.5g、椰粉3g、代糖5g、冻干果粒2g、奇亚籽种子1.5g、圆苞车前子壳2g、复配维生素0.2g。
服用方法同实施例1。
实施例3:
一种益生菌,其特征在于,
包括菌条和轻流质,
所述菌条,包括以下重量份的组分:
益生元2.58g、草莓水果粉0.4g、植物乳杆菌LP45 800亿CFU、乳双歧杆菌BAL53120亿CFU、嗜酸乳杆菌La28 20亿CFU、副干酪乳杆菌YMC1069 25亿CFU、鼠李糖乳杆菌LR51920亿CFU、两歧双歧杆菌TMC3115 20亿CFU、罗伊氏乳杆菌L840 15亿CFU、格氏乳杆菌L83815亿CFU和动物双歧杆菌乳双歧亚种B420 30亿CFU;其中益生元为低聚异麦芽糖0.9g、质量分数小于等于25%的菊粉0.68g、乳糖醇0.4g、低聚果糖0.4g、质量分数小于等于5%的低聚木糖0.2g混合而成;
所述轻流质,包括以下重量份的组分:
脱脂乳粉10g、麦芽糊精10g、浓缩乳清蛋白粉3g、果粉4g、魔芋粉2g、椰粉7g、代糖9g、冻干果粒3g、奇亚籽种子2.5g、圆苞车前子壳5g、复配维生素0.3g。
服用方法同实施例1。
1.研究对象
选取在某医院消化内科门诊及住院部就诊,符合诊断和排除标准的102例轻中度便秘患者作为研究对象,年龄18-60岁,性别不限。排除标准:伴有其它消化道病变、心肝肾功能不全、恶性肿瘤、糖尿病、既往有腹部手术史者、妊娠或哺乳期妇女、试验前4周内曾服用影响本试验观察的药物(抗生素、微生态制剂)、自身免疫性疾病及不能按期复诊及随访者。
2.实验方法
将102例便秘患者随机分为对照组和试验组,对照组直接混水服用本发明实施例2的菌条,早晚各一次;试验组先空腹服用轻流质,再将本发明实施例2的菌条与轻流质混合后服用,早晚各一次;时长为2周。
3.观察指标
(1)观察记录两组患者排便次数、颜色、形状、硬度等指标结果如表1所示。
表1患者排便状况表
受试者每天排便不到1次的人员逐步减少,且变化情况有统计学意义:排便时感觉由两种极端情况趋于集中,其余方面均有一定的改善,在一定程度上缓解了便秘症状。
(2)不同时间检测受试者分辨中菌群数量,结果如表2所示。
表2菌群在肠道定植率表
通过检测受试者粪便中各菌群数量发现,试验组粪便中双歧杆菌属的数量增加度较高,停服1周后,试验组和对照组各菌群量有所下降,但试验组的仍高于对照组。同时发现:在所有受试人群的肠道粪便菌群中致病菌被检测出,随着服用益生菌时间的延长,致病菌相对丰度降低了,说明益生菌在促进有益菌增长的同时也抑制了有害菌的增长。
首先,在饭前空腹服用80~100ml轻流质,轻流质可以起到中和胃酸、胆盐,降低腐蚀性;同时在胃肠消化系统短暂形成一个通畅的管腔环境,以便于益生菌通过。轻流质中圆苞车前子壳所含有效成分Arabynoxylan(多糖分子),能够改善肠壁的润滑条件,轻流质中圆苞车前子壳、魔芋粉富含胶质Mucilage(粘质物)自带吸附力,能够让少量轻流质附着在胃肠道以及胃壁上,进而在短时间内形成一个相对通畅的管腔环境,轻流质中圆苞车前子壳富含的半纤维素,不仅能够抑制碳水化合物、脂质的活性,而且人体中缺少分解半纤维素的酶,胃液的强酸性和所含的消化酶不能对其腐蚀,不能被人体消化,进而在胃中形成一种润滑的保护膜,降低腐蚀性,中和胃酸和胆盐,增加饱腹感,给益生菌提供了更加有利的生存环境。
在空腹服用轻流质作用下,形成相对安全的管腔环境,这时将菌条与100~120ml轻流质充分融合后,为已经穿着冻干包埋防弹衣的菌条又加上了一道厚厚的胶原质保护层。进入人体后,可维护顺利通过顺畅的管腔环境,继而高活性的益生菌在轻流质和冻干包埋技术下保护下又安全通过碱性环境中含有胆汁酸和消化酶的小肠,使得益生菌以较高活性安全到达大肠中,抵达小肠或结肠后与不能被人体消化的轻流质相遇,产生反应,被益生菌所代谢,其剩余轻流质中的胶原质也会在大肠褶皱处与益生菌反应,迅速吸水形成糊状团块,并被菌条与肠内益生菌代谢,让轻流质中的糖类物质经发酵分解为短链脂肪酸,从而阻止胆固醇的合成。当与高脂和低脂膳食同时被食用时,可溶性纤维可同时降低总体胆固醇和低密度脂蛋白(LDL)胆固醇水平。菌条中的罗伊氏乳杆菌可承受胃酸和胆汁的作用而到达小肠的上部并黏附于小肠壁,增加抗炎细胞因子的产生,降低肠道的渗透性。
顺利到达肠道内的菌条在肠腔内、胃肠道上皮以及对肠道菌群的许多细胞水平上的作用下,降低葡萄糖水平和改善胰岛素敏感性等方式来提升代谢健康状况。菌条与肠道微生物群修饰能够恢复受损的葡萄糖耐量异常,影响肠道屏障功能,并因此调节炎性肠道微生物及其组成部分转运,恢复肠道正常通透性,刺激粘液产生,促进粘膜再生,增强肠道屏障功能和定植抗力,产生乳酸物质,能降低肠腔pH,产生酸性环境,以利于有益菌群的生长,增强肠道消化功能。但由于每天人体不健康饮食产生多余的能量,而多余的能量超过了代谢组织的储存能力。菌条与PDX结合能够控制身体脂肪堆积,不仅抑制前脂细胞成脂分化功能(抑制脂肪细胞更多的合成),还能降低了每天约210Kcal/天的能量摄入。不仅如此,轻流质、菌条有效调节肠道菌群,合成人体需要的维生素,还增加了饱食标志物胰多肽(PYY)的表达,来增加饱腹感,降低食欲激素水平,来调节食物摄入量,有助于控制体重和脂肪量,共同增强了肠道健康,维护人体基础代谢。连续补充菌条,将会刺激或增强lgA(免疫球蛋白A)的产生、NK-cell(自然杀伤细胞是机体重要的免疫细胞)的活性、白细胞的吞噬活性、T细胞和B细胞的增殖活性、细胞因子的产生,缓解人体内的乳糖不耐,增强肠道粘膜和系统的免疫反应,菌条与GI微生物组可以持续阻止病原菌的黏附和定植,为肠壁提供能量,竞争营养和定植位点,抵制有害菌,可能减轻免疫系统超敏性,防止粘膜感染,降低了大肠杆菌与粘膜的粘附性,排清体内毒素。当停留在肠道内的食物产生腐败发酵,抑制体内酵素的生成而产生大量硫化氢、氨、酚、吲哚等有毒物质时,将由菌条分解出能明显增加血液中过氧化物歧化酶的含量及其生物活性,有效促进机体内自由基的清除,将体内有害物质毒性降低90%,抑制血浆脂质过氧化反应,延缓机体衰老。顺着粪便排出时,肌肤上产生的暗疮、粉刺、色斑、肤色晦暗无光泽、角质堆积、皮肤老化等问题就会得到很好的改善,为达到更好的美容美白奠定了基础,不仅解决了便秘问题,达到一个健康瘦身的效果。菌条在肠道内定植后,其中的鼠李糖乳菌作用到口腔,继续维护口腔生态平衡,抑制口腔中的病菌。格氏乳杆菌有效改善各类型过敏,调整过敏体质。作为“第二大脑”的肠道,肠脑轴(GBA)整合了管腔条件和信号以及肠道菌群,是连接肠道和大脑的信息交流网络。肠道菌群与脑通过自主神经、肠神经、免疫系统、肠内分泌信号、神经递质、支链氨基酸、胆汁酸、短链脂肪酸、脊髓、下丘脑-垂体-肾上腺轴、肽聚糖等途径和介质进行双向交流。在菌条与肠道菌群相互作用,保持肠道益生菌健康,发酵出更多的短链脂肪酸,促进微生物群落中的内源性细菌调节宿主血清素(5-羟色胺)的合成,促使愉悦感知的启动因子的血清素(5-羟色胺),来刺激和调节人的情绪,让人产生愉悦。不仅如此,菌条维护肠道菌群健康,并产生一种叫做GABA(γ-氨基丁酸)的神经递质,能够帮助我们控制恐惧和焦虑的感觉。且当人体内充分调动好肠神经系统中产生人体50%的多巴胺和约90%的血清素(5-羟色胺)时,将有助于提高记忆力,集中记忆力,让人镇静,减少急躁情绪,带来愉悦感和幸福感,调动工作和学习的积极性,带给人更多快乐。
综上,采用先空腹服用轻流质,再将菌条与轻流质混合后服用的方式,冻干包埋技术处理后的菌条,能够以更高活性顺利进入肠道,让更多活性菌群在肠道定植,维持健康的肠道菌群环境。
临床案例:
案例1:阎某,女,3岁,每天早晚饭前半小时服用,前2天早晚各1支,第三天开始每天1支本发明实施例2的产品。
服用前:
服用后:
停服之后反应:每天都能顺利排便。
案例2:张某,女,26岁。每天早晚饭前半小时服用,前3天早晚各2支,后4天早晚各1支本发明实施例1的产品。
服用后:
反馈结果:服用后有效果,服用时有胀气状态,现在排便很好。
案例3:郑某,男,67岁。第一疗程,每天早晚饭后半小时服用,一次2支本发明实施例3的产品;第二疗程,每天早晚饭后半小时服用,一次2支本发明实施例3的产品;第三疗程,每天早晚饭后半小时服用,一次2支本发明实施例3的产品。
服用前:
第一疗程:
第二疗程:
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种益生菌,其特征在于,
包括菌条和轻流质,
所述菌条,包括以下重量份的组分:
益生元1.1~2.58g、草莓水果粉0.1~0.4g、植物乳杆菌LP45 500~800亿CFU、乳双歧杆菌BAL531 5~20亿CFU、嗜酸乳杆菌La28 5~20亿CFU、副干酪乳杆菌YMC1069 4~25亿CFU、鼠李糖乳杆菌LR519 4~20亿CFU、两歧双歧杆菌TMC3115 8~20亿CFU、罗伊氏乳杆菌L840 4~15亿CFU、格氏乳杆菌L838 4~15亿CFU和动物双歧杆菌乳双歧亚种B420 5~30亿CFU;
所述轻流质,包括以下重量份的组分:
脱脂乳粉3~10g、麦芽糊精1~10g、浓缩乳清蛋白粉1~3g、果粉0.5~4g、魔芋粉0.1~2g、椰粉1~7g、代糖2~9g、冻干果粒0.5~3g、奇亚籽种子0.4~2.5g、圆苞车前子壳1~5g、复配维生素0.1~0.3g。
2.如权利要求1所述的一种益生菌,其特征在于,
包括菌条和轻流质,
所述菌条,包括以下重量份的组分:
益生元1.8g、草莓水果粉0.3g、植物乳杆菌LP45 650亿CFU、乳双歧杆菌BAL531 14亿CFU、嗜酸乳杆菌La28 15亿CFU、副干酪乳杆菌YMC1069 15亿CFU、鼠李糖乳杆菌LR519 12亿CFU、两歧双歧杆菌TMC3115 14亿CFU、罗伊氏乳杆菌L840 10亿CFU、格氏乳杆菌L838 10亿CFU和动物双歧杆菌乳双歧亚种B420 18亿CFU;
所述轻流质,包括以下重量份的组分:
脱脂乳粉7g、麦芽糊精5g、浓缩乳清蛋白粉2g、果粉2g、魔芋粉0.5g、椰粉3g、代糖5g、冻干果粒2g、奇亚籽种子1.5g、圆苞车前子壳2g、复配维生素0.2g。
3.如权利要求1所述的一种益生菌,其特征在于,
所述益生元为低聚异麦芽糖0.5~0.9g、质量分数小于等于25%的菊粉0.2~0.68g、乳糖醇0.2~0.4g、低聚果糖0.1~0.4g、质量分数小于等于5%的低聚木糖0.1~0.2g混合而成。
4.如权利要求1所述的一种益生菌,其特征在于,
所述益生菌为粉剂。
5.一种提升益生菌在肠道内成活率和定植率的方法,基于权利要求1-4任一项所述的益生菌,其特征在于,
饭前0.5~1小时空腹服用80~100ml轻流质,然后将菌条与100~120ml轻流质水融混匀后,再服用下去。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011194725.0A CN112293731A (zh) | 2020-10-30 | 2020-10-30 | 一种提升益生菌在肠道内成活率和定植率的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011194725.0A CN112293731A (zh) | 2020-10-30 | 2020-10-30 | 一种提升益生菌在肠道内成活率和定植率的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112293731A true CN112293731A (zh) | 2021-02-02 |
Family
ID=74333310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011194725.0A Pending CN112293731A (zh) | 2020-10-30 | 2020-10-30 | 一种提升益生菌在肠道内成活率和定植率的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112293731A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113854569A (zh) * | 2021-08-25 | 2021-12-31 | 河北天烨食品科技有限公司 | 益生营养物及其制备方法和提升食用益生菌存活率的方法 |
CN113974168A (zh) * | 2021-09-10 | 2022-01-28 | 北京新华联协和药业有限责任公司 | 一种具有抗过敏功效的复合益生菌组合物及应用、一种制剂 |
CN114250182A (zh) * | 2021-12-23 | 2022-03-29 | 河北一然生物科技股份有限公司 | 益生菌配方设计方法及其在设计调节肠道和免疫的乳双歧杆菌bal531配方中的应用 |
CN115517367A (zh) * | 2022-11-28 | 2022-12-27 | 广东益可维生物技术有限公司 | 副干酪乳杆菌smn-lbk在制备促进肠道健康产品中的应用 |
CN116349815A (zh) * | 2021-12-28 | 2023-06-30 | 自然阳光(上海)日用品有限公司 | 一种能够调节肠道菌群的活菌型益生菌固体饮料生产配方 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1884513A (zh) * | 2006-06-23 | 2006-12-27 | 肖宏 | 益生菌双层包埋微囊工艺 |
CN109481510A (zh) * | 2018-10-11 | 2019-03-19 | 张军毅 | 一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 |
CN111066888A (zh) * | 2019-12-30 | 2020-04-28 | 苏州良品优选科技股份有限公司 | 一种益生菌粉剂 |
-
2020
- 2020-10-30 CN CN202011194725.0A patent/CN112293731A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1884513A (zh) * | 2006-06-23 | 2006-12-27 | 肖宏 | 益生菌双层包埋微囊工艺 |
CN109481510A (zh) * | 2018-10-11 | 2019-03-19 | 张军毅 | 一种有助于改善2型糖尿病及其并发症的合生元复方制剂及其制备方法 |
CN111066888A (zh) * | 2019-12-30 | 2020-04-28 | 苏州良品优选科技股份有限公司 | 一种益生菌粉剂 |
Non-Patent Citations (1)
Title |
---|
潘竹力: "《女人24小时健康保养书》", 31 March 2009, 吉林科学技术出版社 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113854569A (zh) * | 2021-08-25 | 2021-12-31 | 河北天烨食品科技有限公司 | 益生营养物及其制备方法和提升食用益生菌存活率的方法 |
CN113974168A (zh) * | 2021-09-10 | 2022-01-28 | 北京新华联协和药业有限责任公司 | 一种具有抗过敏功效的复合益生菌组合物及应用、一种制剂 |
CN114250182A (zh) * | 2021-12-23 | 2022-03-29 | 河北一然生物科技股份有限公司 | 益生菌配方设计方法及其在设计调节肠道和免疫的乳双歧杆菌bal531配方中的应用 |
CN114250182B (zh) * | 2021-12-23 | 2023-02-17 | 河北一然生物科技股份有限公司 | 益生菌配方设计方法及其在设计调节肠道和免疫的乳双歧杆菌bal531配方中的应用 |
CN116349815A (zh) * | 2021-12-28 | 2023-06-30 | 自然阳光(上海)日用品有限公司 | 一种能够调节肠道菌群的活菌型益生菌固体饮料生产配方 |
CN115517367A (zh) * | 2022-11-28 | 2022-12-27 | 广东益可维生物技术有限公司 | 副干酪乳杆菌smn-lbk在制备促进肠道健康产品中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112293731A (zh) | 一种提升益生菌在肠道内成活率和定植率的方法 | |
CN108004189B (zh) | 一种复合益生乳酸菌粉剂及其制备方法与应用 | |
Guarner | Inulin and oligofructose: impact on intestinal diseases and disorders | |
EP2123168B1 (en) | Lactobacillus paracasei and weight control | |
ES2366542T3 (es) | Lactobacillus probióticos caninos. | |
CA2607949C (en) | Feline probiotic bifidobacteria | |
KR101057357B1 (ko) | 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물 | |
ES2610829T3 (es) | Cepa de Bifidobacterium | |
CN111035014A (zh) | 一种益生菌制剂及其制备方法 | |
JP2003534003A (ja) | ペットフード用新規プロバイオチックス | |
TW200944215A (en) | Lactobacillus isolates having anti-inflammatory activities and uses of the same | |
AU2006253006A1 (en) | Feline probiotic Lactobacilli | |
US20100278795A1 (en) | Lactic acid bacterium-containing preparation | |
CN101146525A (zh) | 与长链多不饱和脂肪酸组合的鼠李糖乳杆菌用于治疗、预防或减少配方喂养婴儿的全身性炎症的用途 | |
CN101146544A (zh) | 鼠李糖乳杆菌用于治疗、预防或减少配方喂养婴儿的全身性炎症的用途 | |
AU2011314299B2 (en) | Compositions and methods for augmenting kidney function | |
US7998470B2 (en) | Compositions and methods improving renal function | |
KR102000170B1 (ko) | 체지방 감소 및 장관면역활성 증진을 위한 건강보조식품 | |
CN109965290B (zh) | 改善肠道菌群代餐粉及其应用 | |
CN114158735B (zh) | 一种益生菌组合物及其应用 | |
KR100866911B1 (ko) | 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 및치료용 조성물 | |
US20230414685A1 (en) | Lactobacillus plantarum pda6 having neurological effects and compositions including the same | |
Gomes et al. | Tuberculous abdominal cocoon | |
TWI423807B (zh) | 具有抗發炎活性的乳桿菌分離株及其用途 | |
Altomare et al. | The intestinal ecosystem and probiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210202 |